Last reviewed · How we verify
NCT05625581
Tofatib Treatment for IgG4-related Disease
trial testing tofacitinib in IgG4-related Disease in 40 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Changhai Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 10 November 2022 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- tofacitinib (tofacitinib) — full drug profile →
Conditions studied
- IgG4-related Disease — all drugs for IgG4-related Disease →
Sponsor
Changhai Hospital
Who can join
Adults 18 to 75, any sex, with IgG4-related Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Compared with cyclophosphamide, the efficacy and safety of tofacitinib in the treatment of active IgG4-related diseases were evaluated.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Current and future advances in practice: IgG4-related disease.
Wallace ZS, Katz G, Hernandez-Barco YG, Baker MC. · · 2024 · cited 33× · PMID 38601138 · DOI 10.1093/rap/rkae020 -
New Developments in the Treatment of IgG4-Related Disease: A Comprehensive Clinical Approach.
González-García A, Starita-Fajardo G, Lucena López D, Iranzo Alcolea MP, et al · · 2025 · cited 3× · PMID 41095851 · DOI 10.3390/jcm14196774 -
IgG4-Related Disease: Emerging Roles of Novel Genetic Variants, Immune Cell Subsets and Therapeutic Targets.
Tedesco L, Ali SB, Erman B, Baris S, et al · · 2025 · cited 1× · PMID 40785550 · DOI 10.1111/all.16686 -
Unraveling the complexity of IgG4-related aortitis and periarteritis: from pathogenesis to clinical practice.
Wang Y, Tian F, Li H. · · 2025 · PMID 40688077 · DOI 10.3389/fimmu.2025.1625456
Verify or expand the search:
- PubMed search for NCT05625581
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of tofacitinib
Trials testing the same drug.
- NCT06418529 — A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoi · completed
- NCT05845723 — Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome · Phase 2 · recruiting
- NCT05400889 — Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies · Phase 2 · unknown
- NCT04624230 — Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis · Phase 3 · active not recruiting
- NCT04496960 — Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome · Phase 1, PHASE2 · active not recruiting
Other recruiting trials for IgG4-related Disease
Currently open trials in the same condition.
- NCT07025330 — A Study of Efgartigimod in Patients With IgG4-Related Disease · Phase 2 · recruiting
- NCT06663618 — Short-term Glucocorticoid Combined with MMF for IgG4-RD · NA · recruiting
Other Changhai Hospital trials
Trials by the same sponsor.
- NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
- NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
- NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
- NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05625581 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
- Last refreshed: 23 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05625581.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing